The dedicated FLOW trial of subcutaneous semaglutide in T2D-related CKD showed a 24% reduction in the composite of major kidney disease events (HR 0.76, 95% CI 0.660.88) and significant reductions in cardiovascular outcomes [22], supporting GLP-1RA therapy as an evidence-based addition for cardiorenal protection in this population
Allergic reactions In a small number of people, semaglutide can cause serious allergic reactions, including anaphylaxis (a sudden, severe allergic reaction with throat closing) and angioedema (swelling)
Possible impact on certain eye conditions in people with diabetes
Adequate hydration is fundamental to preventing constipation in patients taking Ozempic
Additional Reported Adverse Effects Beyond gastroparesis and vision loss, patients have reported numerous other serious adverse effects that have led to FDA warning label updates as evidence accumulated
10.1007/s00125-005-0126-y 227